Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AGRX

Agile Therapeutics (AGRX) Stock Price, News & Analysis

Agile Therapeutics logo

About Agile Therapeutics Stock (NASDAQ:AGRX)

Key Stats

Today's Range
$1.51
$1.52
50-Day Range
$1.43
$1.51
52-Week Range
$0.20
$2.63
Volume
120,900 shs
Average Volume
352,864 shs
Market Capitalization
$10.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.

Receive AGRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agile Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AGRX Stock News Headlines

Prepare Now Before This Looming $2 Trillion D.C. Shock
Millions of traders could get blindsided by this election-year shock on December 18th… And if you do nothing now, you could wind up panicking in the next 30 days… or worse, making a costly mistake.
See More Headlines

AGRX Stock Analysis - Frequently Asked Questions

Agile Therapeutics, Inc. (NASDAQ:AGRX) announced its quarterly earnings data on Tuesday, November, 2nd. The specialty pharmaceutical company reported ($7.20) EPS for the quarter, beating the consensus estimate of ($7.60) by $0.40. The specialty pharmaceutical company earned $1.29 million during the quarter, compared to the consensus estimate of $1.49 million.

Agile Therapeutics shares reverse split before market open on Wednesday, April 27th 2022. The 1-40 reverse split was announced on Wednesday, April 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Agile Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/02/2021
Today
12/11/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AGRX
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Net Income
$-14,470,000.00
Pretax Margin
-36.24%

Debt

Sales & Book Value

Annual Sales
$19.98 million
Book Value
($5.51) per share

Miscellaneous

Free Float
6,822,000
Market Cap
$10.35 million
Optionable
Not Optionable
Beta
1.58

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:AGRX) was last updated on 12/12/2024 by MarketBeat.com Staff
From Our Partners